Lonza Backs Guidance Despite Soft Start to Year
By David Sachs
Lonza said its performance over the first quarter was soft but that it expects the first half to move in line with last year, and backed its full-year guidance.
The Swiss pharmaceutical company said Tuesday that it still expects flat sales growth at constant exchange rates for the year and core earnings before interest, taxes, depreciation and amortization margin in the high 20s.
Sales for the second half year are expected to be solid, reflecting the time of batch releases.
It didn't provide any actual figures for the first quarter.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
May 14, 2024 01:38 ET (05:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks